期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤坏死因子-α抑制剂治疗肉芽肿性多血管炎的现状 被引量：2

下载PDF
导出
摘要 肉芽肿性多血管炎（GPA），既往称为韦格纳肉芽肿（WG），病变主要累及小血管（动脉、静脉及毛细血管），偶尔累及大动脉，主要侵犯上、下呼吸道，绝大多数病例可出现肾脏受累。
作者 任洁 万伟国
机构地区 复旦大学附属华山医院风湿科
出处 《临床内科杂志》 CAS 2016年第7期500-502,共3页 Journal of Clinical Internal Medicine
关键词 肿瘤坏死因子-α抑制剂 肉芽肿性多血管炎 治疗
分类号 R979.5 [医药卫生—药品]
  • 相关文献

参考文献24

  • 1Firestein GS,Buudd RC,Harris ED Jr,等.凯利风湿病学[M].粟占国,唐福林,译.第8版.北京:北京大学医学出版社,2011:1167-1169.
  • 2Manago S, Yonehara S. TNF family ( TNF alpha, beta, FasL, CIMOL) [ J ]. Nihon Rinsho, 2005,63 ( Suppl 4 ) : 202 -206.
  • 3Kallenberg CG, Stegeman CA, Abdulahad WH, et al. Pathoganesis of ANCA-associated vasculitis:new possibilities for intervention [J]. Am J Kidney Dis,2013,62(6) :1176-1187.
  • 4Lamprecht P, Kumanovics G, Mueller A, et al. Elevated monocytie IL-12 and TNF-alpha production in Wegener' s granulomatosis is normalized by cyelophosphamide and eorticosteroid therapy[J].Clin Exp Immunol, 2002,128( 1 ) :181-186.
  • 5Hewins P, Williams JM, Wakelam M J, et al. Activation of Syk in neutrophils by antineutropbil cytoplasm antibodies occurs via Fegamma receptors and CD18 [ J ]. J Am Soe Nephrol,2004,15 (3) :796-808.
  • 6Komocsi A,Lamprecbt P, Csernok E, et al. Peripheral blood and granu- loma CIM( + )CD28( - ) T cells are a major source of interferon-gam- ma and tumor necrosis factor-alpha in Wegener' s granulomatosis [J]. Am J Patho1,2002,160 (5) : 1717-1724.
  • 7Silva F, Cisternas M, Specks U. TNF-alpha blocker therapy and solid malignancy risk in ANCA-associated vasculitis [ J ]. Curr Rheumatol Rep,2012,14(6) :501-508.
  • 8Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener' s granulomatosis [ J ].Rheumatology ( Oxford ) ,2002,41 ( 11 ) : 1303 -1307.
  • 9Booth A. Prospective Study of TNF Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis [J]. J Am Soc Nephrol,2004,15(3) :717-721.
  • 10Kontkanen M, Paimela L, Kaarniranta K. Regression of necrotizing scleritis in Wegener' s granulomatosis after infliximab treatment [ J ]. Aeta Ophthalmo1,2010,88 ( 3 ) : e96-e97.

二级参考文献264

  • 1SCHEINFELD N. Adalimumab(HUMIRA): a review[J]. J Drugs Dermatol, 2003, 2(4): 375-377.
  • 2WEINBLATT ME, KEYSTONE EC, FURST DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial[J]. Arthritis Rheum, 2003, 48(1 ) : 35-45.
  • 3WEINBLATT ME, KEYSTONE EC, FURST DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study[J]. Ann Rheum Dis, 2006, 65(6) : 753-759.
  • 4van de PUTTE LB, ATKINS C, MALAISE M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed [J]. Ann Rheum Dis, 2004, 63(5): 508-516.
  • 5KEYSTONE EC, KAVANAUGH AF, SHARP JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody)in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebocontrolled, 52-week trial[J]. Arthritis Rheum, 2004, 50(5): 1400-1411.
  • 6FURST DE, SCHIFF MH, FLEISCHMANN RM, et al. Adatinmmab, a fully human antitumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis)[J]. J Rheumatol, 2003, 30(12): 2563-2571.
  • 7BREEDVELD FC, WEISMAN MH, KAVANAUGH AF, et al. The PREMIER study: a muhicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment[J]. Arthritis Rheum, 2006, 54(1) : 26-37.
  • 8BURMESTER GR, MARIETFE X, MONTECUCCO C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the research in active rheumatoid arthritis (ReAct) trial[J]. Ann Rheum Dis, 2007, 66(6) : 732-739.
  • 9HETLAND ML, CHRISTENSEN IJ, TARP U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanetcept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry[J]. Arthritis Rheum, 2010, 62(1): 22-32.
  • 10van der HEIJDE D, KIVITZ A, SCHIFF MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheum, 2006, 54 (7): 2136-2146.

共引文献50

同被引文献20

引证文献2

二级引证文献2

临床内科杂志
2016年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部